解放军医学院学报2025，Vol.46Issue(7)：710-715,722,7.DOI:10.12435/j.issn.2095-5227.24110702
外周血炎症指标对生物制剂治疗斑块型银屑病疗效的动态评估研究
Correlation between peripheral blood inflammatory markers and efficacy of biologic agents in treating plaque psoriasis
摘要
Abstract
Background Peripheral blood inflammatory indicators reflect systemic homeostasis during inflammatory responses and immune dysregulation,yet their potential as biomarkers for therapeutic efficacy and prognosis in psoriasis patients receiving biologics warrants further investigation.Objective To analyze the correlation between baseline peripheral blood inflammatory indicators and psoriasis severity in moderate-to-severe plaque psoriasis patients,and evaluate their predictive value for treatment outcomes with infliximab and secukinumab.Methods A retrospective analysis was conducted using data from two randomized,double-blind,controlled phase III clinical trials at our institution.Patients with moderate-to-severe plaque psoriasis treated with biologics from October 2016 to October 2017 and January 2019 to September 2021 were categorized into three groups:infliximab group,secukinumab group and control group.Neutrophil-to-lymphocyte ratio(NLR),systemic immune-inflammation index(SIRI),and aggregate index of systemic inflammation(AISI)were analyzed at baseline,week 4,and week 12.Correlations between these indices and Psoriasis Area and Severity Index(PASI)scores,as well as their association with therapeutic responses,were evaluated.Results A total of 39 patients were enrolled,including 10 caes in the infliximab group(age range:30-61 years;9 males,1 female),22 cases in the secukinumab group(age range:20-51 years;19 males,3 females),and 7 cases in the control group(age range:24-41 years;all males).Correlation analysis revealed positive associations between PASI scores and SIRI(r=0.472,P＜0.05)as well as AISI(r=0.373,P＜0.05).Two-way repeated measures ANOVA demonstrated significant differences in both SIRI and AISI across time dimensions and between groups(P＜0.05).In the time dimension analysis,secukinumab treatment significantly reduced SIRI by 0.28(95%CI:0.07-0.49)at week 4 and 0.38(95%CI:0.17-0.69)at week 12 compared to baseline(P＜0.05),while AISI decreased by 91.17(95%CI:1.27-181.07)and 115.06(95%CI:23.23-206.89)compared with the control group at weeks 4 and 12,respectively(P＜0.05).In the intergroup comparison,Infliximab showed SIRI reduction of 0.43(95%CI:0.01-0.84)at week 4 and 0.63(95%CI:0.26-1.00)at week 12 compared with controls(P＜0.05),with AISI decreasing by 115.92(95%CI:11.45-220.39)and 170.61(95%CI:62.22-279.00)at the corresponding time points(P＜0.05);Secukinumab exhibited greater SIRI reduction of 0.52(95%CI:0.16-0.88)and 0.76(95%CI:0.44-1.09)at weeks 4 and 12 compared with controls(P＜0.05),along with AISI decrease of 137.21(95%CI:45.22-229.20)and 198.03(95%CI:102.58-293.47)at these intervals(P＜0.05).Conclusion The strong correlation between SIRI/AISI indexes and baseline severity of plaque psoriasis suggests their potential utility as objective biomarkers for disease severity assessment.Both infliximab and secukinumab significantly reduced SIRI and AISI values,with secukinumab demonstrating superior efficacy in AISI reduction.Notably,their comparable long-term anti-inflammatory effects provide critical evidence for optimizing biologic therapies in psoriasis management.关键词
英夫利昔单抗/司库奇尤单抗/斑块型银屑病/炎症指标/全身炎症反应指数/全身炎症综合指数Key words
infliximab/secukinumab/plaque psoriasis/peripheral blood inflammatory markers/systemic inflammatory response index/aggregate index of systemic inflammation分类
医药卫生引用本文复制引用
宋翠豪,黄敏,刘晓玲,赵振凯,龚令令,李承新,丁香玉..外周血炎症指标对生物制剂治疗斑块型银屑病疗效的动态评估研究[J].解放军医学院学报,2025,46(7):710-715,722,7.基金项目
北京市自然科学基金项目(7244298) （7244298）
省部级课题 （）
